You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Carboplatin/Paclitaxel

Showing 1 - 25 of 4,872
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Trial in Tampa, Columbus (Carboplatin, Paclitaxel, AZD1775)

Active, not recruiting
  • Lung Cancer
  • Tampa, Florida
  • +1 more
Feb 2, 2023

Advanced Epithelial Ovarian Cancer Trial in Cairo (Carboplatin/paclitaxel)

Completed
  • Advanced Epithelial Ovarian Cancer
  • Carboplatin/paclitaxel
  • Cairo, Egypt
    Pharmacology and toxicology department, Faculty of Pharmacy, Cai
Jul 19, 2023

Oropharynx Squamous Cell Carcinoma Trial in Ann Arbor (Nivolumab, Carboplatin, Paclitaxel)

Active, not recruiting
  • Oropharynx Squamous Cell Carcinoma
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Dec 20, 2022

NSCLC Trial in Shanghai (Pembrolizumab, Paclitaxel, Nab-paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +4 more
  • Shanghai, China
    Zhongshan Hospital Fudan University
Aug 18, 2022

Untreated Advanced or Recurrent Thymic Carcinomas Trial in Chuo (MK-3475, Lenvatinib, Carboplatin)

Not yet recruiting
  • Untreated Advanced or Recurrent Thymic Carcinomas
  • Chuo, Tokyo, Japan
    National Cancer Center Hospital
Apr 16, 2023

Endometrial Carcinoma Trial in Sohag (Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin)

Not yet recruiting
  • Endometrial Carcinoma
  • Sohag, Egypt
    Sohag university Hospital
Oct 25, 2023

Locally Advanced Cancer, Cervical Cancer Trial in France (Carboplatin-Paclitaxel adjuvant chemo)

Recruiting
  • Locally Advanced Cancer
  • Cervical Cancer
  • Carboplatin-Paclitaxel adjuvant chemotherapy
  • Arras, France
  • +5 more
Feb 17, 2022

Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer Trial in Toronto (RP-6306, Carboplatin, Paclitaxel)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Oct 25, 2023

Head and Neck Squamous Cell Carcinoma Trial in United States (TAK-676, Carboplatin, 5-FU)

Completed
  • Head and Neck Squamous Cell Carcinoma
  • Shreveport, Louisiana
  • +3 more
Oct 3, 2023

Locally Advanced Breast Cancer, Chemo Effect Trial in Beijing (inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP)

Recruiting
  • Locally Advanced Breast Cancer
  • Chemotherapy Effect
  • inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
  • Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 28, 2023

NSCLC Trial (Pembrolizumab, Paclitaxel, Nab-paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +4 more
  • (no location specified)
Jan 20, 2022

Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)

Recruiting
  • Breast Cancer
  • Neoadjuvant
  • pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
  • Wuhan, Hubei, China
  • +1 more
Aug 18, 2023

HNSCC, Oral Cancer, PD-1 Trial in Guangzhou (Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses,

Recruiting
  • HNSCC
  • +2 more
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

Head and Neck Squamous Cell Carcinoma, Oral Cancer Trial in Guangzhou (Tirelizumab ,+Carboplatin+albumin-bound paclitaxel)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Oral Cancer
  • Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
  • Guangzhou, Guangdong, China
    Sun yat-sun memorial hospital
Jul 10, 2023

Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom

Active, not recruiting
  • Triple Negative Metastatic Breast Cancer
  • +3 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • +3 more
  • Brussels, Belgium
  • +3 more
Dec 19, 2022

Ovarian Cancer Trial in San Diego (VS-6063, Paclitaxel, Carboplatin)

Recruiting
  • Ovarian Cancer
  • San Diego, California
    University of California San Diego
Feb 1, 2023

Lung Cancer, NSCLC Trial in Houston (MPDL3280A, Carboplatin, Paclitaxel)

Active, not recruiting
  • Lung Cancer
  • Non-Small Cell Lung Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Apr 28, 2022

Adult Solid Tumor Trial in Chicago (Carboplatin, Laboratory Biomarker Analysis, Paclitaxel)

Active, not recruiting
  • Adult Solid Neoplasm
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Jan 25, 2023

Squamous Cell Carcinoma of the Head and Neck Trial in France (Durvalumab with Carboplatin/Paclitaxel)

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Durvalumab with Carboplatin/Paclitaxel
  • Amiens, France
  • +19 more
Mar 14, 2022

Lung Cancer Trial in Carlsbad, Cleveland (ISIS 3521, carboplatin, paclitaxel)

Completed
  • Lung Cancer
  • ISIS 3521
  • +2 more
  • Carlsbad, California
  • +1 more
Dec 1, 2022

Tumors, Metastatic Cancer, Advanced Cancer Trial in United States (Niraparib, TSR-042, Carboplatin-Paclitaxel)

Active, not recruiting
Has Results
  • Neoplasms
  • +6 more
  • Scottsdale, Arizona
  • +7 more
Oct 31, 2022

NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • (no location specified)
Jan 18, 2023

Advanced Cancer Trial in Houston (Temsirolimus, Bevacizumab, Paclitaxel)

Active, not recruiting
  • Advanced Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Oct 11, 2022

Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck Trial in Chicago (Carboplatin,

Recruiting
  • Human Papilloma Virus
  • +4 more
  • Chicago, Illinois
    University Of Chicago Medicine Comprehensive Cancer Center
Jun 3, 2022

Locally Advanced Cervical Cancer Trial in Rome (Pembrolizumab, Carboplatin, Taxol)

Recruiting
  • Locally Advanced Cervical Cancer
  • Rome, Italy
    Fondazione Policlinico Universitario A. Gemelli IRCCS
Aug 24, 2021